The Miami Entrepreneur

Sarepta stock plunges after FDA puts study on hold

Sarepta Therapeutics Inc. shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration. Sarepta disclosed that a patient in a study of a proposed drug for Duchenne muscular dystrophy suffered a “serious adverse event of hypomagnesemia,” or seriously low levels of magnesium in blood. The FDA put the study on clinical hold and requested more information about cases of hypomagnesemia; Sarepta said there had been more non-serious cases. “We will work to share information with FDA with the goal of resuming screening and dosing in the U.S. as quickly as possible,” Chief Scientific Officer Louise Rodino-Klapac said in a statement. Executives planned a conference call for 4:15 Eastern time to discuss the announcement. Sarepta’s stock has declined 20.2% so far this year, in line with a 21.1% decline in the S&P 500 index. [s:spx]

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Leave a Reply

Your email address will not be published.

Previous post LendingTree stock falls after decline in mortgage activity leads to guidance cut
Next post U.S. stocks end higher Thursday, with the Nasdaq Composite rising sharply